Cel-Sci (CVM +3.5%) has rallied after issuing a shareholder letter in which the company...

|About: Cel-Sci Corporation (CVM)|By:, SA News Editor

Cel-Sci (CVM +3.5%) has rallied after issuing a shareholder letter in which the company expressed confidence about the outlook for Phase III trials of its Multikine immunotherapy treatment for head and neck cancer. The company also said it plans to increase the number of patient recruitment centers for the trials to at least 50, comapred with a current 36.